Drugs / EB-CMF
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03678467 | Mar 2021 → Aug 2023 | craniofacial and skeletal defects, neoplasm of jaw | Epibone, Inc. | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EB-CMF | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03678467 ↗ |
| Known as | EpiBone-Craniomaxillofacial | “EpiBone-Craniomaxillofacial (EB-CMF) is an autologous, anatomically shaped bone graft created specifically for the patient's defect, using the patients own adipose-derived...” NCT03678467 ↗ |